A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Vitiligo
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Tranquillo 2
- Sponsors Pfizer
Most Recent Events
- 18 Dec 2023 Status changed from not yet recruiting to recruiting.
- 24 Oct 2023 Planned initiation date changed from 10 Oct 2023 to 27 Oct 2023.
- 12 Oct 2023 New trial record